Spontaneous Bacterial Peritonitis Management

Introduction to SBP

Spontaneous bacterial peritonitis (SBP) is a serious complication in patients with cirrhosis, with high mortality rates, as highlighted by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 1, 2, 3
Patients who survive an episode of SBP have approximately 70% recurrence rate at 1 year without prophylaxis, and poor long-term survival (30-50% at 1 year, 25-30% at 2 years) 3

The standard treatment for active SBP is Cefotaxime 2g IV every 8 hours for 5 days, as recommended by the European Association for the Study of the Liver 3, 1
Immediate empirical antibiotic therapy should be initiated, with Cefotaxime 2g IV every 8 hours for 5 days as the standard treatment, as recommended by the European Association for the Study of the Liver 1
Albumin infusion (1.5 g/kg on day 1, 1 g/kg on day 3) should be considered for patients with renal dysfunction or hyperbilirubinemia, to reduce the risk of renal failure and mortality, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 4, 3, 1
Human albumin administration in addition to antibiotics for active SBP decreases the frequency of hepatorenal syndrome and improves survival, as supported by multiple studies and recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 3, 4

Patients with cirrhosis require prophylactic antibiotics only in specific high-risk scenarios, not universally, as recommended by the European Association for the Study of the Liver 1
Patients with gastrointestinal bleeding and underlying ascites due to cirrhosis should receive short-term prophylaxis (5-7 days) with an antibiotic choice guided by local resistance patterns, such as Cefotaxime, according to the European Association for the Study of the Liver 1
Patients with high risk of first spontaneous bacterial peritonitis (SBP) episode, characterized by ascitic fluid protein <1.5 g/dL and advanced liver disease, impaired renal function, or serum sodium <130 mEq/L, may benefit from prophylaxis with Co-trimoxazole (800 mg sulfamethoxazole/160 mg trimethoprim) daily, as suggested by the European Association for the Study of the Liver 1
The European Association for the Study of the Liver recommends the use of norfloxacin 400 mg once daily taken orally for spontaneous bacterial peritonitis (SBP) prophylaxis, with the goal of preventing SBP in high-risk patients 5

Alternative antibiotics for SBP prophylaxis include:

Antibiotic	Dosage	Recommendation Strength
Norfloxacin	400 mg once daily	First choice for SBP prophylaxis, as recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases [1, 4, 3, 2]
Ciprofloxacin	500 mg once daily	Primary alternative to norfloxacin, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver [1, 2, 3]
Trimethoprim-sulfamethoxazole	800/160 mg daily	Alternative option, as recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases [1, 4, 3, 2]

Patients with cirrhosis and acute gastrointestinal hemorrhage should receive short-term antibiotic prophylaxis (5-7 days) to reduce infection rates, decrease rebleeding risk, and improve survival, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 2, 3, 6
Proton pump inhibitors (PPIs) may increase SBP risk and should be restricted to those with clear indications, as recommended by the European Association for the Study of the Liver 5
Long-term use of quinolones may lead to resistant infections, and consideration should be given to discontinuing quinolone prophylaxis if infection with quinolone-resistant bacteria occurs, as recommended by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 3

Patients who have had SBP have poor long-term survival (30-50% at 1 year) and should be considered for liver transplantation, highlighting the importance of effective prophylaxis and treatment strategies 5, 3
All patients who recover from SBP should be evaluated for liver transplantation, as SBP is a marker of end-stage liver disease with poor prognosis 3
Prophylaxis should be continued indefinitely until liver transplantation or death, as the risk of recurrence remains high 3